Clinical trials: Metastasis Colorectal Cancer
Colorectal Cancer
OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer
This single arm study will assess progression-free survival, feasibility of use and safety of Avastin in combination with 5-FU/FA, oxaliplatin and irinotecan (FOLFOXIRI) as first line treatment in patients with metastatic…
- Trial name
- NCT00940303
- Testing
- 5-FU, bevacizumab [Avastin], irinotecan
- Where
- 17 sites in Germany
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer
This 2 arm study assessed the efficacy and safety of maintenance treatment with Avastin (bevacizumab) + Xeloda (capecitabine), after initial treatment with Xeloda + oxaliplatin + Avastin, in patients with metastatic colorectal…
- Trial name
- NCT00623805
- Testing
- Bevacizumab, Capecitabine, Oxaliplatin
- Where
- 10 sites in Turkey (Türkiye)
- Volunteers
- 123 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
Real-World Treatment Patterns and Effectiveness of Anti-EGFR- and Anti-VEGF-based Therapies in Left-sided RAS Wild-Type Metastatic Colorectal Cancer
The aim of this study is to learn how doctors treat a type of metastatic colorectal cancer in everyday medical practice. The study focuses on patients whose cancer started on the left side of the colon and does not have specific…
- Trial name
- NCT07909122
- Testing
- Anti-EGFR-Based Therapy, Anti-VEGF-Based Therapy
- Volunteers
- 1 people
- Sponsor
- Pfizer
Liver Metastases, Colorectal Cancer
Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases
The purpose of this study is to determine the effect of adecatumumab alone or following FOLFOX in patients with R0 resected liver metastases from CRC (colorectal carcinoma) and to compare the effect to FOLFOX alone.
- Trial name
- MT201-204 (NCT00866944)
- Testing
- Adecatumumab, Adecatumumab and FOLFOX, FOLFOX 4
- Where
- 16 sites in France, Germany
- Volunteers
- 35 people
- Sponsor
- Amgen Research (Munich) GmbH
Colorectal Cancer
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Cancer of the Colon or Rectum
This prospective observational study will evaluate the safety and efficacy of first-line Avastin (bevacizumab) in combination with standard chemotherapy in routine clinical practice in patients with metastatic cancer of the colon…
- Trial name
- NCT01830647
- Where
- Montenegro
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche
Colorectal Neoplasms
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.
- Trial name
- NCT03659448
- Testing
- SGM-101
- Where
- 11 sites in United States, Germany and 2 more
- Volunteers
- 300 people
- Sponsor
- Surgimab
Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with…
- Trial name
- NCT04793958
- Testing
- MRTX849, Cetuximab, mFOLFOX6 Regimen
- Where
- 419 sites in United States, Argentina and 30 more
- Volunteers
- 461 people
- Sponsor
- Mirati Therapeutics Inc.
Metastatic Colorectal Cancer
A Study of ES104 in Patients With Metastatic Colorectal Cancer
The purpose of this open-label, Multicenter Phase I/II study is to evaluate the safety, tolerability, preliminary anti-tumor efficay, pharmacokinetics, anti-drug antibodies and biomarkers of ES104 in patients with unresectable…
- Trial name
- NCT05167448
- Testing
- ES104
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.
Unresectable Metastatic Colorectal Cancer
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered concurrently with FOLFOX chemotherapy, followed by…
- Trial name
- NCT04991948
- Testing
- CYAD-101, FOLFOX, Pembrolizumab
- Where
- 5 sites in United States, Belgium
- Volunteers
- 34 people
- Sponsor
- Celyad Oncology SA
Neoplasms
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022.
- Trial name
- NCT02817633
- Testing
- TSR-022, Nivolumab, TSR-042
- Where
- 89 sites in United States, South Korea and 1 more
- Volunteers
- 463 people
- Sponsor
- Tesaro, Inc.
MSS, RAS-mutant Colorectal Cancer
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
This is a multicenter, open-label, Phase 1B/2 study to evaluate the safety and assess the preliminary anti-tumor activity of binimetinib administered in combination with nivolumab or nivolumab + ipilimumab in adult patients with…
- Trial name
- NCT03271047
- Testing
- binimetinib, nivolumab, ipilimumab
- Where
- 50 sites in United States, Belgium and 3 more
- Volunteers
- 75 people
- Sponsor
- Pfizer
Colorectal Cancer
A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in sparticipants with HER2-Abnormally Expressed locally advanced or metastatic colorectal cancer (CRC).
- Trial name
- NCT07653685
- Testing
- TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection, TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)
- Where
- 31 sites in China
- Volunteers
- 71 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Colorectal Neoplasms
TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread
This study will assess the safety and anticancer activity of TQB2922 injection given under the skin together with chemotherapy in adults with colorectal cancer that has spread, cannot be removed by surgery, and has no RAS or BRAF…
- Trial name
- NCT07844187
- Testing
- TQB2922 injection (subcutaneous administration), Oxaliplatin, Calcium folinate (leucovorin calcium)
- Where
- 16 sites in China
- Volunteers
- 64 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Metastatic Colorectal Cancer
Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer
This is a Phase III, randomized, two arms, double-blind (patient and assessor blinded), parallel active non inferiority controlled clinical trial with a 2:1 allocation.
- Trial name
- NCT03288987
- Testing
- Bevacizumab + FOLFIRI-3
- Where
- 22 sites in Iran
- Volunteers
- 126 people
- Sponsor
- AryoGen Pharmed Co.
Metastatic Colorectal Cancer (mCRC)
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
This study is a phase Ⅱ, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with Irinotecan and SG001 in Patients with Metastatic Colorectal Cancer…
- Trial name
- NCT06089330
- Testing
- JMT101, SG001, Irinotecan
- Volunteers
- 102 people
- Sponsor
- Shanghai JMT-Bio Inc.
Colorectal Cancer (CRC), Colon Cancer Liver Metastases
Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases
The goal of this clinical trial is to learn if a new injectable drug (IP-001), administered after standard liver tumor ablation, can help prevent cancer from returning in people (males/females, ≥18 years old) with colorectal…
- Conditions
- Colorectal Cancer (CRC), Colon Cancer Liver Metastases, Rectal Cancer, Rectal Cancer With Liver Metastases
- Trial name
- INJECTABL-3 (NCT07321847)
- Testing
- 1.0% IP-001 for Injection, a 10 mg/mL solution of IP-001 in water, 1.0% IP-001 for Injection, a 1 mg/mL solution of IP-001 in water., Microwave (thermal) tumor ablation
- Volunteers
- 717 people
- Sponsor
- Immunophotonics, Inc.
Colorectal Neoplasms
Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer
This study will include two parts: Phase I part is a dose-escalation study to assess the safety of increasing doses of TG6002 in combination with oral flucytosine (5-FC) in consecutive cohorts of 3 to 6 patients with colorectal…
- Trial name
- NCT04194034
- Testing
- TG6002, Flucytosine (5-FC)
- Where
- 3 sites in France, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Transgene
Colorectal Cancer
Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00007826
- Testing
- BCG vaccine, monoclonal antibody 105AD7 anti-idiotype vaccine, alum adjuvant
- Where
- United Kingdom
- Sponsor
- Onyvax
Metastatic Colorectal Cancer, Colorectal Cancer Metastatic
Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
This is a Phase 2, randomized, open-label, 3-arm trial in the ratio of 1:1:1 to either Sym004 (Arm A) versus each of its component monoclonal antibodies (mAbs), futuximab (Arm B) or modotuximab (Arm C), in genomically-selected…
- Conditions
- Metastatic Colorectal Cancer, Colorectal Cancer Metastatic, Carcinoma
- Trial name
- NCT03549338
- Testing
- Sym004, Futuximab, Modotuximab
- Where
- 18 sites in United States, Germany and 2 more
- Volunteers
- 2 people
- Sponsor
- Symphogen A/S
Metastatic Colorectal Cancer
Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
The purpose of this study is to determine if Cediranib when added to chemotherapy is more effective than chemotherapy alone in prolonging life expectancy and slowing disease progression in patients with previously untreated…
- Trial name
- HORIZON II (NCT00399035)
- Testing
- Cediranib, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), XELOX (Capecitabine and Oxaliplatin)
- Where
- 90 sites in Argentina, Australia and 13 more
- Volunteers
- 1,254 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.